Powder: -20°C for 3 years | In solvent: -80°C for 1 year
T-705RTP sodium is a selective and GTP-competitive of influenza virus RNA polymerase(IC50 of 0.14 μM and a Ki of 1.52 μM), has potent anti-influenza virus activity.
产品描述 | T-705RTP sodium is a selective and GTP-competitive of influenza virus RNA polymerase(IC50 of 0.14 μM and a Ki of 1.52 μM), has potent anti-influenza virus activity. |
体外活性 | T-705RTP sodium and T-705RMP are detected in MDCK cells treated with T-705. influenza virus RNA polymerase activity in a dose-dependent and a GTP-competitive manner inhibited by T-705RTP sodium[1]. T-705RTP sodium inhibits the incorporation of ATP and GTP in a competitive manner (Ki of 7.72 and 1.56 μM, respectively). T-705RTP sodium inhibits the incorporation of CTP in a mixed-type manner(Ki of 11.3 μM), and also inhibits the incorporation of UTP in a noncompetitive manner[2]. The incorporation of a single molecule of T-705RTP (10-1000 μM) inhibits influenza virus RNA strand extension[2]. |
分子量 | 552.145 |
分子式 | C10H15FN3NaO15P3 |
CAS No. | 356783-10-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
T-705RTP sodium 356783-10-3 Others T 705RTP sodium T705RTP sodium Inhibitor inhibitor inhibit